Results for tag: "Bydureon"

Bydureon is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as Endocrine and Metabolic Disorders Drugs. Bydureon is a long-acting form of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by stimulating the release of insulin from the pancreas and decreasing the amount of glucose produced by the liver. It also helps to reduce appetite and slow the absorption of glucose from the intestines. Bydureon is available in the form of an injection and is typically taken once a week. It is usually prescribed in combination with other diabetes medications, such as metformin, sulfonylureas, and thiazolidinediones. The Bydureon market includes companies such as AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi. These companies are involved in the research, development, and marketing of Bydureon and other Endocrine and Metabolic Disorders Drugs. Show Less Read more